FDA's decision not to require Ad Comm for Duchenne Muscular Dystrophy may not be positive.

From Yahoo Finance: 2025-06-25 12:15:00

Roth Capital analyst Boobalan Pachaiyappan suggests that the FDA’s decision not to require an Ad Comm for deramiocel for Duchenne Muscular Dystrophy may not be positive news. The firm maintains a Buy rating and $31 price target on Capricor shares. A potential positive Ad Comm panel vote could pressure new leadership to approve deramiocel.



Read more at Yahoo Finance: No Ad Comm ‘not necessarily positive’ for Capricor, says Roth Capital